| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PNOC |
| Uniprot No | Q13519 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-176aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSSCQRDCL TCQEKLHPAL DSFDLEVCIL ECEEKVFPSP LWTPCTKVMA RSSWQLSPAA PEHVAAALYQ PRASEMQHLR RMPRVRSLFQ EQEEPEPGME EAGEMEQKQL QKRFGGFTGA RKSARKLANQ KRFSEFMRQY LVLSMQSSQR RRTLHQNGNV |
| 预测分子量 | 21 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PNOC(Prepronociceptin)重组蛋白的3篇参考文献示例，内容基于典型研究方向概括：
---
1. **标题**: *"Expression and Purification of Recombinant PNOC in Escherichia coli for Functional Studies"*
**作者**: Smith A, et al.
**摘要**: 本研究报道了通过大肠杆菌表达系统高效制备重组PNOC蛋白的方法，优化了纯化流程并验证其生物活性，为后续受体结合实验提供基础材料。
2. **标题**: *"Structural Characterization of PNOC-Derived Peptides Using Recombinant Protein Technology"*
**作者**: Tanaka K, et al.
**摘要**: 利用重组PNOC蛋白进行酶解和质谱分析，解析了其衍生肽段(如nociceptin)的构效关系，揭示了关键功能结构域在疼痛调节中的作用。
3. **标题**: *"In Vivo Analgesic Effects of Recombinant PNOC in Rodent Models"*
**作者**: Lee J, et al.
**摘要**: 通过在小鼠模型中注射重组PNOC蛋白，证实其通过结合NOP受体调控痛觉信号通路，为开发新型镇痛药物提供了实验依据。
---
**说明**：上述文献为模拟示例，实际研究中建议通过PubMed或Web of Science等平台检索具体论文(关键词：PNOC recombinant protein, nociceptin expression)。若需真实文献，可补充提供研究方向细节以便进一步筛选。
**Background of PNOC Recombinant Protein**
The PNOC (Prepronociceptin) gene encodes a precursor protein that is proteolytically processed to produce nociceptin (orphanin FQ), a neuropeptide involved in modulating pain perception, stress responses, and emotional behaviors. Nociceptin acts as the endogenous ligand for the opioid receptor-like 1 (ORL1 or NOP) receptor, which belongs to the G protein-coupled receptor (GPCR) family. Unlike classical opioids, nociceptin exhibits unique pharmacological properties, including paradoxical hyperalgesic or anti-opioid effects under certain conditions, making it a critical target for pain management and neurological research.
Recombinant PNOC protein is generated through biotechnological methods, typically by inserting the PNOC gene into expression vectors (e.g., bacterial, mammalian, or insect cell systems) to enable large-scale production. The recombinant protein retains the functional domains required for receptor binding and activation, allowing researchers to study its structure, signaling mechanisms, and interactions in vitro or in vivo. Applications include elucidating nociceptin's role in pain pathways, addiction, anxiety, and neurodegenerative disorders, as well as screening potential therapeutics targeting the NOP receptor.
Advances in recombinant technology have improved the purity, stability, and bioactivity of PNOC-derived products, facilitating drug discovery and mechanistic studies. Challenges remain in optimizing expression systems to mimic post-translational modifications and ensure proper folding. Nonetheless, PNOC recombinant proteins continue to serve as vital tools for unraveling the complexity of nociceptin signaling and developing novel analgesics with reduced side effects compared to traditional opioids.
×
